BioWorld. Link to homepage.
BioWorld
BioWorld MedTech
BioWorld Asia
BioWorld Science
Data Snapshots
BioWorld
BioWorld MedTech
Infographics: Dynamic digital data analysis
Special reports
Aging
Alzheimer's disease
Artificial intelligence
Biosimilars
Coronavirus
Infographics: Dynamic digital data analysis
Israel
IVDs on the rise
Radiopharmaceuticals
Rise of obesity
Top Biopharma Trends of 2023
Top Med-tech Trends of 2023
Top Preclinical Trends of 2023
Premium reports
BioWorld Financings Reports
Disease Incidence & Prevalence Summaries
BioWorld. Link to homepage.
sign in
Sign Out
My Account
Subscribe
BioWorld - Friday, April 19, 2024
See today's BioWorld
Home
» Small Rebound for Ariad Stock on Positive CHMP Vote for Iclusig
X
Upgrade your daily dose of biopharma and medtech news
Subscribe to BioWorld™ news services
See subscription options
To read the full story,
subscribe
or
sign in
.
Small Rebound for Ariad Stock on Positive CHMP Vote for Iclusig
Nov. 25, 2013
By
Jennifer Boggs
No Comments
Shares of Ariad Pharmaceuticals Inc. gained 35.5 percent Friday after the European Committee for Medicinal Products for Human Use (CHMP) recommended that leukemia drug Iclusig (ponatinib) remain on the market in Europe.
BioWorld